Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,802

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Tuberculosis
Interventions
BIOLOGICAL

Bacillus Calmette - Guerin

The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of BCG .

BIOLOGICAL

placebo of Bacillus Calmette - Guerin

The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of placebo of BCG .

All Listed Sponsors
collaborator

Air Force Military Medical University, China

OTHER

collaborator

Proswell Medical Corporation

INDUSTRY

collaborator

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

collaborator

Jurong Centers for Disease Control and Prevention

UNKNOWN

lead

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

INDUSTRY

NCT02795260 - Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy) | Biotech Hunter | Biotech Hunter